首页> 外文期刊>Kaohsiung Journal of Medical Sciences >Clinical experience in diagnosis and treatment of malignant gastrointestinal stromal tumors
【24h】

Clinical experience in diagnosis and treatment of malignant gastrointestinal stromal tumors

机译:恶性胃肠道间质瘤诊治的临床经验

获取原文
获取外文期刊封面目录资料

摘要

This study investigated the clinical pathologic character of malignant gastrointestinal stromal tumors (MGIST), their treatment with surgery, and evaluated the efficacy of imatinib postoperation. A total of 68 MGIST patients were enrolled. Of these, 27 patients underwent imatinib auxiliary therapy (treatment group) and 41 underwent imatinib therapy (control group). The therapeutic effects on the two groups were compared using χ 2 test analysis after follow-up of two years. The expressions of CD117, CD34, S100, Vimentin, and alpha smooth-muscle actin (SMA) were detected by immunohistochemistry methods. Of the 68 cases, 28 showed potential MGIST, whereas 40 had MGIST. Haemorrhagia or necrosis, abundant cell, manifest heteromorphism, and caryocinesia were observed in varying degrees. The positive rates of CD117, CD34, Vimentin, S100, and SMA were 89.7% (61/62), 88.2% (60/62), 73.5% (50/62), 41.1% (28/62) and 25.0% (17/62), respectively. The recurrence rate in the treatment group?was significantly lower than that in the control group ( p ?
机译:这项研究调查了恶性胃肠道间质瘤(MGIST)的临床病理特征,其手术治疗,并评估了伊马替尼术后的疗效。共有68名MGIST患者入组。其中,有27例患者接受了伊马替尼辅助治疗(治疗组),有41例接受了伊马替尼治疗(对照组)。随访两年后,采用χ2检验分析比较两组的疗效。用免疫组织化学方法检测CD117,CD34,S100,波形蛋白和α平滑肌肌动蛋白(SMA)的表达。在68例中,有28例显示出潜在的MGIST,而40例具有MGIST。出血或坏死,丰富的细胞,明显的异质性,和肌成瘾的观察到不同程度。 CD117,CD34,Vimentin,S100和SMA的阳性率分别为89.7%(61/62),88.2%(60/62),73.5%(50/62),41.1%(28/62)和25.0%( 17/62)。治疗组的复发率明显低于对照组(p <0.01)。我们得出结论,CD117和CD34可能是MGIST诊断中最有价值的标志物,而MGIST的诊断取决于病理。手术是治疗此类患者的更好方法,伊马替尼是预防复发和转移的更有效靶标药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号